関連する実験動画
Updated: Aug 17, 2026

08:18
A Model of Chronic Nutrient Infusion in the Rat
Published on: August 14, 2013
まとめ
肥満の個人は,非肥満の対照群と比較して,アラニンに対する血グルカゴン反応の低下を示しています. この違いは,吸収後の状態と断食状態の両方で持続し,肥満におけるグルコース調節の変化を強調しています.
科学分野:
- エンドクリノロジー エンドクリノロジー
- メタボリック研究.
- 肥満に関する研究.
背景:
- グルカゴンは,グルコースのホメオスタシスに重要な役割を果たします.
- 肥満は,代謝調節の変化と関連しています.
- アラニン注入は,グルカゴン分泌を刺激するために使用されます.
研究 の 目的:
- アラニン注入に対するプラズマ・グルカゴン反応に対する肥満の影響を調査する.
- 吸収後および断食後の肥満および非肥満患者のグルカゴン反応を比較するために.
主な方法:
- 肥満と非肥満の被験者にアラニン注入を投与した.
- 血におけるグルカゴン濃度測定.
- 吸収後の状態と84時間の断食状態の両方で評価された応答.
主要な成果:
- 肥満の被験者は,非肥満の対照群と比較して,アラニン注入後の血グルカゴン濃度の有意な鈍化した増加を示した.
- 基礎グルカゴン濃度は,不肥満の被験者では断食後に増加したが,肥満の被験者では変化しなかった.
- 肥満者におけるグルカゴン反応の低下は,栄養を与えられた状態と断食状態の両方で観察されました.
結論:
- 肥満は,アミノ酸刺激に対するグルカゴン分泌反応の障害によって特徴付けられます.
- グルカゴン調節の変化は,肥満における代謝失調に寄与する可能性があります.
- 断食は,肥満者におけるグルカゴンの鈍化反応を正常化しません.
さらに関連する動画
08:47Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy
Published on: December 7, 2017
08:13Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT)
Published on: January 7, 2018
関連する概念動画
Hormones Regulating Blood Glucose
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
Obesity
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Insulin and C-peptide are co-secreted in...
Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.